Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Key facts

Sponsor

SWOG Cancer Research Network

Principal Investigator

Rachna Shroff, MD

SWOG Cancer Research Network

Intervention

Cisplatin(drug)

Enrollment

452 enrolled

Eligibility

18 years · All sexes

Timeline

2019 – 2024

Study locations (30)

• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
• Kingman Regional Medical Center, Kingman, Arizona, United States
• Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
• Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
• Mayo Clinic in Arizona, Scottsdale, Arizona, United States
• University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Carcinoma of gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT06901622
  Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
  The First Affiliated Hospital of Zhengzhou University
• RECRUITINGNCT07337850
  Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
  Tata Memorial Centre
• RECRUITINGPHASE2NCT06440993
  Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• ACTIVE NOT RECRUITINGPHASE2NCT05712356
  A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
  Lisata Therapeutics, Inc.
• ENROLLING BY INVITATIONPHASE3NCT06671418
  Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
  Erasmus Medical Center
• RECRUITINGNCT05404347
  NGS in Gallbladder Cancer and Response to Treatment
  Banaras Hindu University

See all trials for Carcinoma of gallbladder and extrahepatic biliary tract →